US20110284418A1 - Container for inhalation anesthetic - Google Patents

Container for inhalation anesthetic Download PDF

Info

Publication number
US20110284418A1
US20110284418A1 US13/196,884 US201113196884A US2011284418A1 US 20110284418 A1 US20110284418 A1 US 20110284418A1 US 201113196884 A US201113196884 A US 201113196884A US 2011284418 A1 US2011284418 A1 US 2011284418A1
Authority
US
United States
Prior art keywords
container
pharmaceutical product
inhalation anesthetic
anesthetic
inhalation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/196,884
Inventor
Ralph V. Rudzinski
Ralph A. Lessor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc filed Critical Baxter International Inc
Priority to US13/196,884 priority Critical patent/US20110284418A1/en
Assigned to BAXTER INTERNATIONAL INC. reassignment BAXTER INTERNATIONAL INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LESSOR, RALPH A., RUDZINSKI, RALPH V.
Assigned to BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A. reassignment BAXTER INTERNATIONAL INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAXTER INTERNATIONAL INC.
Publication of US20110284418A1 publication Critical patent/US20110284418A1/en
Priority to US16/252,341 priority patent/US20190151600A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A61M16/18—Vaporising devices for anaesthetic preparations
    • A61M16/183—Filling systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics

Definitions

  • the present invention relates to containers for liquid inhalation anesthetics, more particularly, to aluminum containers that are suitable for storing halogenated inhalation anesthetics.
  • Containers such as those of the present invention, are used to store the liquid anesthetic agent, and to dispense it to a device for administering the agent to a patient.
  • vaporizers which mate with the container, receive the liquid anesthetic through an orifice in the container, vaporize the anesthetic, mix it with oxygen and optionally other gases, and mete out the gaseous mixture to the patient.
  • Inhalation anesthetics have traditionally been stored in glass containers. These containers, however, possess certain drawbacks. Glass requires careful handling to avoid breakage, and when breakage does occur, product is lost and injury may occur. In addition, it has been theorized that the inhalation anesthetic may react with components of the glass, leading to certain degradation products. Cf. U.S. Pat. No. 5,990,176.
  • plastic containers for inhalation anesthetics made of certain plastics have been proposed. Cf. WO 99/34762, U.S. Pat. Nos. 6,074,668 and 6,162,443 and U.S. Patent Application Publication No. U.S. 2001/0000729 A1. While plastic containers are less likely to break than glass containers, they are still susceptible to breakage under common use conditions. Moreover, many plastics tend to be vapor permeable, allowing the inhalation anesthetic to escape the container and ambient vapors to enter the container over time, leading to possible contamination. Also, plastic containers are subject to deformation when exposed to elevated temperatures, which may be required during processing and treatment of the inhalation anesthetic-containing containers. Moreover, inhalation anesthetics have strong organic solvent properties, which typically will dissolve and/or react with the plastic material, leading to measurable impurities in the inhalation anesthetic.
  • Containers for sevoflurane have also been made of stainless steel.
  • U.S. Pat. No. 5,990,176 describes a container made of glass, plastic or stainless steel for holding sevoflurane.
  • Metal containers have been used for various types of pharmaceutical products, as well as food and beverages.
  • U.S. Pat. No. 6,008,273 describes an epoxy resin for coating the inside of a metal container for use as a food or beverage container.
  • the present invention overcomes the drawbacks of the prior art by providing a pharmaceutical product comprising a halogenated inhalation anesthetic stored within an aluminum container. It has been found that aluminum containers provide structural integrity, inertness and vapor-barrier properties that are well-suited for storage and handling of such inhalation anesthetics. In addition, aluminum is light in weight, resistant to heat-deformation, easily recycled and protects the inhalation anesthetic from light-induced degradation.
  • the container is provided with an orifice for filling or removing the halogenated inhalation anesthetic, and a closure for the orifice.
  • the closure preferably has a lining that helps the closure retain the desirable characteristics of the aluminum container.
  • the closure may be provided with a valve assembly for regulating the flow of anesthetic.
  • the closure may also be provided with indexing elements specially configured and unique to the particular inhalation anesthetic housed in the container to help ensure the anesthetic is administered only by the vaporizer for which it is designed.
  • the aluminum container may also be provided with a lining for added inertness.
  • the container will be bottle-shaped.
  • Halogenated inhalation anesthetics are well known and commercially available. These include sevoflurane (fluoromethyl-2,2,2-trifluoro/1/(tri-fluoromethyl)ethyl ether), desflurane (2-difluromethyl 1,2,2,2-tetrafluoroethyl ether), isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether), enflurane (2-chloro-1,1,2-trifluoroethyl difluoromethyl ether), methoxyflurane (2,2-dichloro-1,1-difluoroethyl methyl ether) and halothane (2-bromo-2-chloro-1,1,1-trifluoroethane), all of which are liquids at ambient conditions.
  • Aluminum containers suitable for use in the present invention are commercially available. Typically, they will be manufactured in the size and shape of the glass containers in which inhalation anesthetics are currently commercially sold. Commercially sold containers are bottle-shaped, i.e., they are outfitted with a neck whose mouth (orifice) can be sealed shut with a closure.
  • the aluminum containers of the present invention may be lined or unlined. Although the prior art hypothesizes that aluminum oxide present in glass containers may lead to degradation of the inhalation anesthetic, it has been found that no such degradation problem arises in the present invention. However, in some cases it may be desirable to provide the aluminum container with an inert lining to prevent the formation or release of flakes or small particles of aluminum during the manufacture of the container and formation of threads on the neck of the container. These flakes, while not a problem from a safety standpoint, may appear in the liquid anesthetic and be unpleasing from a cosmetic or visual standpoint. Therefore, it is desirable to prevent formation of particles or flakes during the bottle manufacturing process.
  • Suitable lining materials are those which demonstrate no significant solubility in the inhalation anesthetic, i.e., do not render the inhalation anesthetic unusable.
  • These lining materials include lacquers and enamels, and preferably contain an epoxyphenolic resin.
  • Examples of lining materials that are commercially available include Type Nos. 7407P and 7940 HL/F from HOBA Industrie-Chemie GmbH, Bodelshausen, Germany.
  • 7407P is a highly flexible liner suitable for aluminum containers having a thickness of 8-14 microns, and is based upon epoxyphenolic resin having a solid content of about 30 parts by weight, a delivered viscosity of about 90 sec. DIN 4 mm 20 C, a density of about 0.99 g/ml. The thickness of the liner may be less for certain applications.
  • the containers of the present invention will have an orifice for filling or removing the halogenated inhalation anesthetic, as well as a closure for the orifice.
  • the closure should be chosen so as not to compromise the characteristics of the container, namely, it should provide structural integrity, inertness and vapor barrier properties.
  • the closure will typically be a cap, such as those used on commercially available glass containers.
  • the cap may be screw-on, snap-on or of a more elaborate design for fitting with commercially available vaporizers which are used to dispense the inhalation anesthetics.
  • the closure may be made of aluminum or other metal, or of a polymer material.
  • closures that are lined with the aforementioned lacquers, or with a polytetrafluoroethylene (PTFE).
  • PTFE polytetrafluoroethylene
  • One such lining is commercially available under the name “Plytrax 100” and has a PTFE facing with a polyethylene foam backing, available from Norton Performance Plastics Corporation, 150 Day Road, Wayne N.J. 07470-4699, a subsidiary of Saint-Gobain Performance Plastics.
  • valve assembly means a closure provided with at least one valve for regulating flow of the anesthetic.
  • valve assembly means a closure provided with at least one valve for regulating flow of the anesthetic.
  • Such closures are well known in the art, cf. U.S. Pat. Nos. 5,505,236 and 5,617,906.
  • These valve assemblies serve to, alternately, close the orifice of the container to minimize loss of anesthetic from the container, and open the orifice by way of interaction with the vaporizer to deliver anesthetic to the vaporizer.
  • valve assemblies may be screwed or snapped onto the container.
  • closures may be provided with indexing elements that allow the container to mate only with a vaporizer having corresponding indexing elements. This helps to ensure that an anesthetic is administered only through the vaporizer for which it was designed.
  • the container is bottle-shaped, whose neck (orifice) is sealed closed with a cap or valve assembly.
  • the neck may be threaded, to allow screw-on of the cap or valve assembly.
  • the valve assembly may be provided with indexing elements having a configuration that is unique and specific to the particular inhalation anesthetic stored in the container. The indexing elements helps assure that the container storing a particular inhalation anesthetic will only mate to a vaporizer designed for that inhalation anesthetic.
  • the container size and shape may be varied to indicate a particular type of inhalation anesthetic as well as to avoid mistaken mixing of different types of anesthetics in a vaporizer.
  • the container may be a bottle sized container for holding the final drug product, or may be in a larger tank or drum size for use during shipping, mixing or holding of the inhalation anesthetic in the bulk drug form or in a crude manufactured form awaiting final distillation.
  • the aluminum may be in the form of a liner or inner layer of another type of container, such as a plastic or steel container.

Abstract

A pharmaceutical product includes an inhalation anesthetic stored within an aluminum container. According to such a product, the interior of the aluminum container is provided with an inert lining comprising an epoxyphenolic resin, and the inhalation anesthetic is selected from the group consisting of sevoflurane, desflurane, isoflurane, enflurane, methoxyflurane and halothane.

Description

  • This application is a continuation of U.S. Ser. No. 09/952,039, filed Sep. 13, 2001, that claims benefit of U.S. Ser. No. 60/233,302, filed Sep. 15, 2000, both of which are hereby incorporated herein by reference in their entirety in the present application.
    • BACKGROUND
  • The present invention relates to containers for liquid inhalation anesthetics, more particularly, to aluminum containers that are suitable for storing halogenated inhalation anesthetics.
  • Containers, such as those of the present invention, are used to store the liquid anesthetic agent, and to dispense it to a device for administering the agent to a patient. These devices are known in the art as “vaporizers,” which mate with the container, receive the liquid anesthetic through an orifice in the container, vaporize the anesthetic, mix it with oxygen and optionally other gases, and mete out the gaseous mixture to the patient.
  • Inhalation anesthetics have traditionally been stored in glass containers. These containers, however, possess certain drawbacks. Glass requires careful handling to avoid breakage, and when breakage does occur, product is lost and injury may occur. In addition, it has been theorized that the inhalation anesthetic may react with components of the glass, leading to certain degradation products. Cf. U.S. Pat. No. 5,990,176.
  • A number of patents have taught the use of plastic containers for inhalation anesthetics and, in particular, sevoflurane. For example, U.S. Pat. No. 4,250,334 teaches the use of “Kel-F” plastic for a container for holding sevoflurane. “Kel-F” is understood to be the trade name for chlorotrifluoroethylene. U.S. Pat. No. 5,679,576 teaches the use of a container lined with PTFE, or polytetrafluoroethylene, for holding sevoflurane. U.S. Pat. No. 5,505,236, teaches the use of a plastic container with an inhalation anesthetic. While not specifically naming the inhalation anesthetic, it is believed that the commercial embodiment of the system shown in the '236 patent has been used with the anesthetic sevoflurane. Despite the existence of these patents teaching plastic containers to hold sevoflurane, a number of additional patents have recently issued that have taught the use of particular types of plastic for containers to hold sevoflurane. See, e.g., U.S. Pat. Nos. 6,074,668 (polyethylene napthalate), 6,083,514 (polymethylpentene) and 6,162,443 (polypropylene, polyethylene and ionomeric resins). The present invention presents an alternative type of container (aluminum) to hold sevoflurane.
  • In addition, containers for inhalation anesthetics made of certain plastics have been proposed. Cf. WO 99/34762, U.S. Pat. Nos. 6,074,668 and 6,162,443 and U.S. Patent Application Publication No. U.S. 2001/0000729 A1. While plastic containers are less likely to break than glass containers, they are still susceptible to breakage under common use conditions. Moreover, many plastics tend to be vapor permeable, allowing the inhalation anesthetic to escape the container and ambient vapors to enter the container over time, leading to possible contamination. Also, plastic containers are subject to deformation when exposed to elevated temperatures, which may be required during processing and treatment of the inhalation anesthetic-containing containers. Moreover, inhalation anesthetics have strong organic solvent properties, which typically will dissolve and/or react with the plastic material, leading to measurable impurities in the inhalation anesthetic.
  • Containers for sevoflurane have also been made of stainless steel. For example, U.S. Pat. No. 5,990,176 describes a container made of glass, plastic or stainless steel for holding sevoflurane. Metal containers have been used for various types of pharmaceutical products, as well as food and beverages. U.S. Pat. No. 6,008,273 describes an epoxy resin for coating the inside of a metal container for use as a food or beverage container.
    • SUMMARY
  • The present invention overcomes the drawbacks of the prior art by providing a pharmaceutical product comprising a halogenated inhalation anesthetic stored within an aluminum container. It has been found that aluminum containers provide structural integrity, inertness and vapor-barrier properties that are well-suited for storage and handling of such inhalation anesthetics. In addition, aluminum is light in weight, resistant to heat-deformation, easily recycled and protects the inhalation anesthetic from light-induced degradation.
  • In further embodiments, the container is provided with an orifice for filling or removing the halogenated inhalation anesthetic, and a closure for the orifice. The closure preferably has a lining that helps the closure retain the desirable characteristics of the aluminum container. Alternatively, the closure may be provided with a valve assembly for regulating the flow of anesthetic. The closure may also be provided with indexing elements specially configured and unique to the particular inhalation anesthetic housed in the container to help ensure the anesthetic is administered only by the vaporizer for which it is designed.
  • The aluminum container may also be provided with a lining for added inertness. Typically, the container will be bottle-shaped.
    • DETAILED DESCRIPTION OF VARIOUS EMBODIMENTS
  • Halogenated inhalation anesthetics are well known and commercially available. These include sevoflurane (fluoromethyl-2,2,2-trifluoro/1/(tri-fluoromethyl)ethyl ether), desflurane (2-difluromethyl 1,2,2,2-tetrafluoroethyl ether), isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether), enflurane (2-chloro-1,1,2-trifluoroethyl difluoromethyl ether), methoxyflurane (2,2-dichloro-1,1-difluoroethyl methyl ether) and halothane (2-bromo-2-chloro-1,1,1-trifluoroethane), all of which are liquids at ambient conditions.
  • Aluminum containers suitable for use in the present invention are commercially available. Typically, they will be manufactured in the size and shape of the glass containers in which inhalation anesthetics are currently commercially sold. Commercially sold containers are bottle-shaped, i.e., they are outfitted with a neck whose mouth (orifice) can be sealed shut with a closure.
  • The aluminum containers of the present invention may be lined or unlined. Although the prior art hypothesizes that aluminum oxide present in glass containers may lead to degradation of the inhalation anesthetic, it has been found that no such degradation problem arises in the present invention. However, in some cases it may be desirable to provide the aluminum container with an inert lining to prevent the formation or release of flakes or small particles of aluminum during the manufacture of the container and formation of threads on the neck of the container. These flakes, while not a problem from a safety standpoint, may appear in the liquid anesthetic and be unpleasing from a cosmetic or visual standpoint. Therefore, it is desirable to prevent formation of particles or flakes during the bottle manufacturing process.
  • Suitable lining materials are those which demonstrate no significant solubility in the inhalation anesthetic, i.e., do not render the inhalation anesthetic unusable. These lining materials include lacquers and enamels, and preferably contain an epoxyphenolic resin. Examples of lining materials that are commercially available include Type Nos. 7407P and 7940 HL/F from HOBA Industrie-Chemie GmbH, Bodelshausen, Germany. 7407P is a highly flexible liner suitable for aluminum containers having a thickness of 8-14 microns, and is based upon epoxyphenolic resin having a solid content of about 30 parts by weight, a delivered viscosity of about 90 sec. DIN 4 mm 20 C, a density of about 0.99 g/ml. The thickness of the liner may be less for certain applications.
  • The containers of the present invention will have an orifice for filling or removing the halogenated inhalation anesthetic, as well as a closure for the orifice. The closure should be chosen so as not to compromise the characteristics of the container, namely, it should provide structural integrity, inertness and vapor barrier properties. The closure will typically be a cap, such as those used on commercially available glass containers. The cap may be screw-on, snap-on or of a more elaborate design for fitting with commercially available vaporizers which are used to dispense the inhalation anesthetics. The closure may be made of aluminum or other metal, or of a polymer material. Particularly preferred are closures that are lined with the aforementioned lacquers, or with a polytetrafluoroethylene (PTFE). One such lining is commercially available under the name “Plytrax 100” and has a PTFE facing with a polyethylene foam backing, available from Norton Performance Plastics Corporation, 150 Day Road, Wayne N.J. 07470-4699, a subsidiary of Saint-Gobain Performance Plastics.
  • Alternatively, the closure may be provided with a valve assembly. As used herein, “valve assembly” means a closure provided with at least one valve for regulating flow of the anesthetic. Such closures are well known in the art, cf. U.S. Pat. Nos. 5,505,236 and 5,617,906. These valve assemblies serve to, alternately, close the orifice of the container to minimize loss of anesthetic from the container, and open the orifice by way of interaction with the vaporizer to deliver anesthetic to the vaporizer. Like caps, valve assemblies may be screwed or snapped onto the container.
  • In addition, these closures may be provided with indexing elements that allow the container to mate only with a vaporizer having corresponding indexing elements. This helps to ensure that an anesthetic is administered only through the vaporizer for which it was designed.
  • In a preferred embodiment, the container is bottle-shaped, whose neck (orifice) is sealed closed with a cap or valve assembly. The neck may be threaded, to allow screw-on of the cap or valve assembly. The valve assembly may be provided with indexing elements having a configuration that is unique and specific to the particular inhalation anesthetic stored in the container. The indexing elements helps assure that the container storing a particular inhalation anesthetic will only mate to a vaporizer designed for that inhalation anesthetic. The container size and shape may be varied to indicate a particular type of inhalation anesthetic as well as to avoid mistaken mixing of different types of anesthetics in a vaporizer. Various alloys of aluminum may be used for the container, and still fall within the scope of the present invention. The container may be a bottle sized container for holding the final drug product, or may be in a larger tank or drum size for use during shipping, mixing or holding of the inhalation anesthetic in the bulk drug form or in a crude manufactured form awaiting final distillation. Also, the aluminum may be in the form of a liner or inner layer of another type of container, such as a plastic or steel container.

Claims (8)

1. A pharmaceutical product comprising an inhalation anesthetic stored within an aluminum container,
the interior of the aluminum container provided with an inert lining comprising an epoxyphenolic resin, and
the inhalation anesthetic selected from the group consisting of sevoflurane, desflurane, isoflurane, enflurane, methoxyflurane and halothane.
2. The pharmaceutical product of claim 1 wherein the inert lining has a thickness of approximately 8-14 microns.
3. The pharmaceutical product of claim 1 wherein the container has an orifice for filling or removing the inhalation anesthetic, and a closure for the orifice.
4. The pharmaceutical product of claim 3 wherein the closure comprises a cap.
5. The pharmaceutical product of claim 4 wherein the cap is lined with polytetrafluoroethylene (PTFE).
6. The pharmaceutical product of claim 3 wherein the closure comprises a valve assembly for regulating flow of the inhalation anesthetic.
7. The pharmaceutical product of claim 6 wherein the closure includes indexing elements selected to correspond to indexing elements of a vaporizer.
8. The pharmaceutical product of claim 1 wherein the container is bottle-shaped.
US13/196,884 2000-09-15 2011-08-02 Container for inhalation anesthetic Abandoned US20110284418A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/196,884 US20110284418A1 (en) 2000-09-15 2011-08-02 Container for inhalation anesthetic
US16/252,341 US20190151600A1 (en) 2000-09-15 2019-01-18 Container For Inhalation Anesthetic

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23330200P 2000-09-15 2000-09-15
US09/952,039 US8001961B2 (en) 2000-09-15 2001-09-13 Container for inhalation anesthetic
US13/196,884 US20110284418A1 (en) 2000-09-15 2011-08-02 Container for inhalation anesthetic

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/952,039 Continuation US8001961B2 (en) 2000-09-15 2001-09-13 Container for inhalation anesthetic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/252,341 Continuation US20190151600A1 (en) 2000-09-15 2019-01-18 Container For Inhalation Anesthetic

Publications (1)

Publication Number Publication Date
US20110284418A1 true US20110284418A1 (en) 2011-11-24

Family

ID=22876707

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/952,039 Active 2027-10-14 US8001961B2 (en) 2000-09-15 2001-09-13 Container for inhalation anesthetic
US13/196,884 Abandoned US20110284418A1 (en) 2000-09-15 2011-08-02 Container for inhalation anesthetic
US16/252,341 Abandoned US20190151600A1 (en) 2000-09-15 2019-01-18 Container For Inhalation Anesthetic

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/952,039 Active 2027-10-14 US8001961B2 (en) 2000-09-15 2001-09-13 Container for inhalation anesthetic

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/252,341 Abandoned US20190151600A1 (en) 2000-09-15 2019-01-18 Container For Inhalation Anesthetic

Country Status (17)

Country Link
US (3) US8001961B2 (en)
EP (1) EP1317301B1 (en)
JP (2) JP5801024B2 (en)
KR (2) KR100881241B1 (en)
CN (1) CN1228103C (en)
AR (2) AR031873A1 (en)
AT (1) ATE297779T1 (en)
AU (2) AU9083301A (en)
BR (1) BR0113917B1 (en)
CA (1) CA2420035C (en)
DE (1) DE60111546T2 (en)
ES (1) ES2244656T3 (en)
MX (1) MXPA03002340A (en)
PT (1) PT1317301E (en)
TW (1) TW523409B (en)
WO (1) WO2002022195A2 (en)
ZA (1) ZA200301153B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW523409B (en) * 2000-09-15 2003-03-11 Baxter Int Container for inhalation anesthetic
US20080087283A1 (en) * 2006-10-16 2008-04-17 Abbott Laboratories Apparatus for and related method of inhibiting lewis acid degradation in a vaporizer
US9278048B2 (en) * 2009-05-06 2016-03-08 Baxter International, Inc. Pharmaceutical product and method of use
WO2015024100A1 (en) * 2013-08-19 2015-02-26 Schmidt Klaus Michael Non-anesthetic protective gases in combination with liquid anesthetic agents for organ protection
EP3325061B1 (en) 2015-07-20 2021-05-05 Medical Developments International Limited Inhaler device for inhalable liquids
KR102574310B1 (en) 2015-07-20 2023-09-05 메디컬 디벨롭먼츠 인터네셔널 리미티드 Inhaler device for inhalable liquids
AU2016297678B2 (en) 2015-07-20 2020-10-08 Medical Developments International Limited Inhaler device for inhalable liquids
AU2017325107B2 (en) 2016-09-06 2022-10-06 Medical Developments International Limited Inhaler device for inhalable liquids
BE1024432B1 (en) * 2016-11-02 2018-02-19 Central Glass Company, Limited METHOD FOR WASHING OF SEVOFLURAN STORAGE CONTAINER AND METHOD FOR STORAGE OF SEVOFLURAN
JP2018075346A (en) * 2016-11-02 2018-05-17 セントラル硝子株式会社 Method for washing sevoflurane storage container and method for storing sevoflurane
UY37974A (en) 2017-11-20 2019-06-28 Lanxess Deutschland Gmbh ALUMINUM GLASSES CONTAINING DICARBONIC DIESTERS
CN111053760A (en) * 2019-12-27 2020-04-24 江苏恒丰强生物技术有限公司 Inhalation sevoflurane for pets
KR102200764B1 (en) 2020-02-18 2021-01-08 가톨릭대학교 산학협력단 Anesthesia container pressing device attached on anesthesia vaporizer
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045784A (en) * 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
US8001961B2 (en) * 2000-09-15 2011-08-23 Baxter International Inc. Container for inhalation anesthetic

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE515475A (en) * 1951-11-13
US4250334A (en) 1979-12-26 1981-02-10 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
JPH01283225A (en) * 1988-05-10 1989-11-14 Toyo Jozo Co Ltd Aerosol preparation for treating infectious disease of bovine respiratory organ and treating method using the same
JPH0267374A (en) * 1988-08-31 1990-03-07 Takeuchi Press Ind Co Ltd Aerosol container
US5617906A (en) 1991-01-24 1997-04-08 The Boc Group Plc Container for anaesthetic agent
US6596260B1 (en) * 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
JP2780616B2 (en) * 1993-11-22 1998-07-30 東洋製罐株式会社 Epoxy paint
US5505236A (en) 1994-04-04 1996-04-09 Abbott Laboratories Anesthetic vaporizer filling system
JP2865554B2 (en) * 1994-04-08 1999-03-08 セントラル硝子株式会社 Gas chromatographic analysis of fluoromethyl-1,1,1,3,3,3-hexafluoroisopropyl ether
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
EP1166811B1 (en) * 1995-04-14 2006-12-06 SmithKline Beecham Corporation Metered dose inhaler for fluticasone propionate
GB9517998D0 (en) * 1995-09-04 1995-11-08 Bioglan Lab Ltd Compositions and device for their administration
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
DE19709704C2 (en) * 1997-03-10 1999-11-04 Michael Georgieff Use of a liquid preparation of xenon for intravenous administration when inducing and / or maintaining anesthesia
US6008273A (en) 1997-05-09 1999-12-28 The Dexter Corporation Waterborne coating compositions for metal containers
JP4498480B2 (en) * 1997-12-10 2010-07-07 千寿製薬株式会社 Nasal formulation
US6083514A (en) 1998-01-09 2000-07-04 Abbott Laboratories Polymethylpentene container for an inhalation anesthetic
US6074668A (en) 1998-01-09 2000-06-13 Abbott Laboratories Container for an inhalation anesthetic
US6162443A (en) * 1998-01-09 2000-12-19 Abbott Laboratories Container for an inhalation anesthetic
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045784A (en) * 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
US8001961B2 (en) * 2000-09-15 2011-08-23 Baxter International Inc. Container for inhalation anesthetic

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
http://www.dictionary.com/browse/inert, obtained from the web on 10/20/16. *

Also Published As

Publication number Publication date
AR100298A2 (en) 2016-09-28
ES2244656T3 (en) 2005-12-16
US20020068767A1 (en) 2002-06-06
ATE297779T1 (en) 2005-07-15
ZA200301153B (en) 2004-01-23
US20190151600A1 (en) 2019-05-23
WO2002022195A3 (en) 2002-08-08
JP2004508146A (en) 2004-03-18
EP1317301B1 (en) 2005-06-15
CA2420035A1 (en) 2002-03-21
BR0113917B1 (en) 2010-12-28
PT1317301E (en) 2005-08-31
KR20030030001A (en) 2003-04-16
CA2420035C (en) 2010-02-16
EP1317301A2 (en) 2003-06-11
JP5746002B2 (en) 2015-07-08
KR100901049B1 (en) 2009-06-04
CN1452501A (en) 2003-10-29
DE60111546D1 (en) 2005-07-21
AU2001290833B2 (en) 2006-02-02
DE60111546T2 (en) 2006-05-11
US8001961B2 (en) 2011-08-23
AU9083301A (en) 2002-03-26
KR100881241B1 (en) 2009-02-05
WO2002022195A2 (en) 2002-03-21
KR20080070080A (en) 2008-07-29
MXPA03002340A (en) 2003-06-06
BR0113917A (en) 2003-07-22
JP5801024B2 (en) 2015-10-28
CN1228103C (en) 2005-11-23
TW523409B (en) 2003-03-11
AR031873A1 (en) 2003-10-08
JP2012030119A (en) 2012-02-16

Similar Documents

Publication Publication Date Title
US20190151600A1 (en) Container For Inhalation Anesthetic
AU2001290833A1 (en) Container for inhalation anesthetic
US6558679B2 (en) Container for an inhalation anesthetic
RU2720158C2 (en) Inhaler device for inhalation liquids
US9278048B2 (en) Pharmaceutical product and method of use
JP7043399B2 (en) Inhaler device for inhalable liquids
US20070221217A1 (en) Container for an inhalation anesthetic
US20080044442A1 (en) Container for an Inhalation Anesthetic

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAXTER INTERNATIONAL INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RUDZINSKI, RALPH V.;LESSOR, RALPH A.;REEL/FRAME:027064/0920

Effective date: 20011102

AS Assignment

Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAXTER INTERNATIONAL INC.;REEL/FRAME:027116/0532

Effective date: 20111024

Owner name: BAXTER INTERNATIONAL INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAXTER INTERNATIONAL INC.;REEL/FRAME:027116/0532

Effective date: 20111024

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION